ANTIPROLIFERATIVE ACTIVITY;
ARTICLE;
CONTROLLED STUDY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
OXIDATION;
STRUCTURE ACTIVITY RELATION;
Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells [J]
Millet A, Bettaieb A, Renaud F, et al. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells [J]. Gastroenterology 2002, 123(1):235-246.
Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer [J]
Yasuda H, Yamaya M, Nakayama K, et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer [J]. J Clin Oncol 2006, 24(4):688-694.
Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer [J]
Siemens DR, Heaton JP, Adams MA, et al. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer [J]. Urology 2009, 74(4):878-883.
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents [J]
Moharram S, Zhou A, Wiebe LI, et al. Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents [J]. J Med Chem 2004, 47(7):1840-1846.
Anticancer properties of the novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo [J]
Maksimovic-Ivanic D, Mijatovic S, Harhaji L, et al. Anticancer properties of the novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo [J]. Mol Cancer Ther 2008, 7(3):510-520.
Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid [J]
Chen L, Zhang Y, Kong X, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid [J]. J Med Chem 2008, 51(15):4834-4838.
Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents [J]
Lai Y, Shen L, Zhang Z, et al. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents [J]. Bioorg Med Chem Lett 2010, 20(22):6416-6420.
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents [J]
Ling Y, Ye X, Ji H, et al. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents [J]. Bioorg Med Chem 2010, 18(10):3448-3456.
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity [J]
Ling Y, Ye X, Zhang Z, et al. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity [J]. J Med Chem 2011, 54(9):3251-3259.
Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells [J]
Tang X, Gu X, Ai H, et al. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells [J]. Bioorg Med Chem Lett 2012, 22(2):801-805.
Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells [J]
Kang N, Zhang JH, Qiu F, et al. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells [J]. J Nat Prod 2010, 73(6):1058-1063.
Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates [J]
Xu J, Yang J, Ran Q, et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates [J]. Bioorg Med Chem Lett 2008, 18(16):4741-4744.
Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity [J]
Wang L, Li D, Wang C, et al. Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity [J]. Mini-Rev Med Chem 2011, 11(10):910-919.
The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents [J]
Wang L, Li D, Xu S, et al. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents [J]. Eur J Med Chem 2012, 52(1):242-250.
